NASDAQ:VIVE - Viveve Medical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.26 +0.42 (+22.83 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$2.26
Today's Range$1.86 - $2.26
52-Week Range$1.60 - $8.75
Volume945,033 shs
Average Volume367,049 shs
Market Capitalization$54.72 million
P/E Ratio-1.07
Dividend YieldN/A
Beta-0.44

About Viveve Medical (NASDAQ:VIVE)

Viveve Medical logoViveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

Receive VIVE News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VIVE
CUSIPN/A
Phone720-696-8100

Debt

Debt-to-Equity Ratio1.55
Current Ratio6.47
Quick Ratio6.00

Price-To-Earnings

Trailing P/E Ratio-1.07
Forward P/E Ratio-1.47
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.29 million
Price / Sales4.62
Cash FlowN/A
Price / CashN/A
Book Value$0.61 per share
Price / Book3.70

Profitability

EPS (Most Recent Fiscal Year)($2.11)
Net Income$-36,950,000.00
Net Margins-269.24%
Return on Equity-437.98%
Return on Assets-103.63%

Miscellaneous

Employees103
Outstanding Shares31,270,000

Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions

What is Viveve Medical's stock symbol?

Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."

How were Viveve Medical's earnings last quarter?

Viveve Medical Inc (NASDAQ:VIVE) posted its quarterly earnings data on Thursday, May, 10th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.05. The firm earned $3.70 million during the quarter, compared to analysts' expectations of $4.68 million. Viveve Medical had a negative net margin of 269.24% and a negative return on equity of 437.98%. View Viveve Medical's Earnings History.

What price target have analysts set for VIVE?

8 equities research analysts have issued 1 year price objectives for Viveve Medical's shares. Their forecasts range from $6.00 to $11.00. On average, they anticipate Viveve Medical's stock price to reach $9.3333 in the next year. View Analyst Ratings for Viveve Medical.

What are Wall Street analysts saying about Viveve Medical stock?

Here are some recent quotes from research analysts about Viveve Medical stock:
  • 1. Mizuho analysts commented, "We expect the trends in utilization and pricing to continue in 2018. FDA Approval of IDE to Conduct VIVEVE2 Clinical Trial. The FDA approved Viveve’s IDE to conduct a sexual function study in the U.S. The study is expected to start in 2Q18 and will include approximately 250 patients across 25 clinical sites in the U.S. and Canada. The primary endpoint will measure the mean change from baseline in the total FSFI (Female Sexual Function Index) at 12 months. Data from the study is expected in 2H19. Cash Position and Upcoming Catalysts. Viveve’s current cash position stands at approximately $55.7 mil following a recent $35.0 mil equity offering in February." (3/20/2018)
  • 2. Maxim Group analysts commented, "4Q17 revenue of $5.1M, up 108% y/y, was inline with the preannouncement." (3/16/2018)

Who are some of Viveve Medical's key competitors?

Who are Viveve Medical's key executives?

Viveve Medical's management team includes the folowing people:
  • Ms. Patricia K. Scheller, CEO & Chairperson (Age 58)
  • Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 60)
  • Mr. Scott C. Durbin, CFO & Sec. (Age 49)
  • Mr. Martin Kerber, VP of Operations
  • Mr. Jim B. Robbins, VP of Fin. & Admin. (Age 54)

When did Viveve Medical IPO?

(VIVE) raised $13 million in an initial public offering on Tuesday, June 14th 2016. The company issued 1,600,000 shares at a price of $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.

Has Viveve Medical been receiving favorable news coverage?

Headlines about VIVE stock have trended positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Viveve Medical earned a coverage optimism score of 0.29 on Accern's scale. They also assigned news coverage about the company an impact score of 47.04 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Viveve Medical's major shareholders?

Viveve Medical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (4.90%), BlackRock Inc. (2.50%), Wexford Capital LP (2.23%), Acuta Capital Partners LLC (2.19%), ING Groep NV (1.38%) and Northern Trust Corp (0.81%). Company insiders that own Viveve Medical stock include James G Atkinson, Patricia Scheller, Scott Durbin and Stonepine Capital Management,. View Institutional Ownership Trends for Viveve Medical.

Which institutional investors are buying Viveve Medical stock?

VIVE stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Wexford Capital LP, Acuta Capital Partners LLC, ING Groep NV, Northern Trust Corp, BlackRock Inc. and Spark Investment Management LLC. Company insiders that have bought Viveve Medical stock in the last two years include James G Atkinson, Patricia Scheller, Scott Durbin and Stonepine Capital Management,. View Insider Buying and Selling for Viveve Medical.

How do I buy shares of Viveve Medical?

Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viveve Medical's stock price today?

One share of VIVE stock can currently be purchased for approximately $2.26.

How big of a company is Viveve Medical?

Viveve Medical has a market capitalization of $54.72 million and generates $15.29 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Viveve Medical employs 103 workers across the globe.

How can I contact Viveve Medical?

Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]


MarketBeat Community Rating for Viveve Medical (VIVE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  207
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe VIVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Viveve Medical (NASDAQ:VIVE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Viveve Medical in the last 12 months. Their average twelve-month price target is $9.3333, suggesting that the stock has a possible upside of 312.98%. The high price target for VIVE is $11.00 and the low price target for VIVE is $6.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.883.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.3333$9.4286$10.00$10.40
Price Target Upside: 312.98% upside180.61% upside172.48% upside116.22% upside

Viveve Medical (NASDAQ:VIVE) Consensus Price Target History

Price Target History for Viveve Medical (NASDAQ:VIVE)

Viveve Medical (NASDAQ:VIVE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018Craig HallumDowngradeBuy ➝ HoldHighView Rating Details
4/17/2018Stifel NicolausInitiated CoverageBuy ➝ Buy$6.00HighView Rating Details
3/20/2018MizuhoReiterated RatingBuy$10.00MediumView Rating Details
3/16/2018Maxim GroupReiterated RatingBuy$11.00HighView Rating Details
1/5/2018Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$8.00LowView Rating Details
1/4/2018Ladenburg ThalmannReiterated RatingBuyLowView Rating Details
10/23/2017CowenSet Price TargetBuy$11.00N/AView Rating Details
5/25/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$10.00MediumView Rating Details
5/17/2017B. RileyReiterated RatingBuy$10.00MediumView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Viveve Medical (NASDAQ:VIVE) Earnings History and Estimates Chart

Earnings by Quarter for Viveve Medical (NASDAQ:VIVE)

Viveve Medical (NASDAQ:VIVE) Earnings Estimates

2018 EPS Consensus Estimate: ($1.35)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.41)($0.39)($0.40)
Q2 20182($0.38)($0.30)($0.34)
Q3 20182($0.37)($0.25)($0.31)
Q4 20182($0.37)($0.23)($0.30)

Viveve Medical (NASDAQ VIVE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018($0.44)($0.49)$4.68 million$3.70 millionViewN/AView Earnings Details
3/15/2018Q4 2017($0.47)($0.53)$5.09 million$5.10 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.42)($0.50)$4.10 million$4.07 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.33)($0.54)$3.24 million$3.08 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.5120)($0.57)$2.70 million$3.04 millionViewN/AView Earnings Details
2/16/2017Q4 2016($0.48)($0.55)$2.10 million$2.45 millionViewN/AView Earnings Details
11/10/2016Q316($0.48)($0.46)$1.70 million$1.85 millionViewN/AView Earnings Details
8/11/2016Q216($0.48)($0.66)$1.33 million$1.56 millionViewListenView Earnings Details
5/13/2016Q1 2016($0.43)($0.55)$1.29 million$1.28 millionViewN/AView Earnings Details
3/24/2016Q4 2015($0.48)($0.56)$0.75 million$0.75 millionViewN/AView Earnings Details
11/13/2015Q3 2015($0.48)($0.72)$0.58 million$0.58 millionViewN/AView Earnings Details
8/14/2015Q2 2015($0.64)$0.16 million$0.07 millionViewN/AView Earnings Details
5/15/2015Q1 2015($0.72)($1.12)$0.03 million$0.04 millionViewN/AView Earnings Details
3/16/2015Q4 2014($1.52)$0.03 millionViewN/AView Earnings Details
11/14/2014Q3 2014($24.00)($4.16)$0.05 million$0.02 millionViewN/AView Earnings Details
5/15/2014Q1 2014($8.00)($8.00)$0.29 million$0.05 millionViewN/AView Earnings Details
3/28/2014Q4 2013($8.00)($8.00)$0.48 million$0.21 millionViewN/AView Earnings Details
11/14/2013Q3 2013($8.00)($8.00)$0.40 million$0.35 millionViewN/AView Earnings Details
8/14/2013Q2 2013($8.00)($8.00)$0.37 millionViewN/AView Earnings Details
5/15/2013Q1 2013($24.00)($24.00)$0.31 million$0.35 millionViewN/AView Earnings Details
3/28/2013Q4 2012($32.00)($32.00)ViewN/AView Earnings Details
11/14/2012Q3 2012($32.00)$80.00ViewN/AView Earnings Details
8/14/2012Q2 2012($40.00)($28.80)ViewN/AView Earnings Details
5/15/2012Q1 2012($32.00)($33.60)ViewN/AView Earnings Details
3/30/2012Q4 2011($24.00)ViewN/AView Earnings Details
11/14/2011Q3 2011($10.40)ViewN/AView Earnings Details
8/12/2011Q2 2011($4.80)ViewN/AView Earnings Details
5/16/2011Q1 2011($128.80)ViewN/AView Earnings Details
3/29/2011Q4 2010$7.20ViewN/AView Earnings Details
8/16/2010Q2 2010($8.00)ViewN/AView Earnings Details
5/14/2010Q1 2010($14.40)ViewN/AView Earnings Details
3/30/2010Q4 2009($16.00)ViewN/AView Earnings Details
11/10/2009Q3 2009($9.60)ViewN/AView Earnings Details
8/10/2009Q2 2009($8.00)ViewN/AView Earnings Details
5/7/2009Q1 2009($9.60)ViewN/AView Earnings Details
3/12/2009Q4 2008($5.60)ViewN/AView Earnings Details
11/13/2008Q3 2008($7.20)ViewN/AView Earnings Details
8/6/2008Q2 2008($17.60)ViewN/AView Earnings Details
5/15/2008Q1 2008($20.00)ViewN/AView Earnings Details
3/5/2008Q4 2007($21.60)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Viveve Medical (NASDAQ:VIVE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Viveve Medical (NASDAQ VIVE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 35.10%
Institutional Ownership Percentage: 64.83%
Insider Trading History for Viveve Medical (NASDAQ:VIVE)
Insider Trading History for Viveve Medical (NASDAQ:VIVE)

Viveve Medical (NASDAQ VIVE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2017Scott DurbinCFOBuy5,000$5.25$26,250.0011,568View SEC Filing  
3/17/2017James G AtkinsonDirectorBuy375,000$4.00$1,500,000.0011,525View SEC Filing  
3/17/2017Patricia SchellerCEOBuy12,500$4.00$50,000.0045,164View SEC Filing  
6/17/2016James G. AtkinsonInsiderBuy100,000$5.00$500,000.00View SEC Filing  
6/17/2016Patricia SchellerCEOBuy6,000$5.00$30,000.00View SEC Filing  
6/17/2016Scott DurbinCFOBuy1,500$5.00$7,500.00View SEC Filing  
6/17/2016Stonepine Capital Management,Major ShareholderBuy300,000$5.00$1,500,000.00View SEC Filing  
9/23/20145Am Partners Ii, LlcMajor ShareholderBuy5,215,664$0.53$2,764,301.92View SEC Filing  
9/23/2014Daniel JanneyDirectorBuy1,895,788$0.53$1,004,767.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Viveve Medical (NASDAQ VIVE) News Headlines

Source:
DateHeadline
Q2 2018 Earnings Forecast for Viveve Medical Issued By Zacks Investment Research (VIVE)Q2 2018 Earnings Forecast for Viveve Medical Issued By Zacks Investment Research (VIVE)
www.americanbankingnews.com - May 21 at 1:02 AM
VIVE: Q1 Results: Disappointing But Not All Was Bad. Guidance Intact But That May Now Be More ChallengingVIVE: Q1 Results: Disappointing But Not All Was Bad. Guidance Intact But That May Now Be More Challenging
finance.yahoo.com - May 17 at 4:40 PM
BRIEF-Viveve Announces Initiation Of Viveve II Clinical StudyBRIEF-Viveve Announces Initiation Of Viveve II Clinical Study
www.reuters.com - May 16 at 9:49 AM
Viveve Announces Initiation of VIVEVE II Clinical StudyViveve Announces Initiation of VIVEVE II Clinical Study
finance.yahoo.com - May 16 at 9:49 AM
 Analysts Anticipate Viveve Medical (VIVE) Will Post Quarterly Sales of $5.79 Million Analysts Anticipate Viveve Medical (VIVE) Will Post Quarterly Sales of $5.79 Million
www.americanbankingnews.com - May 14 at 4:47 AM
Viveve Medical (VIVE) Expected to Announce Earnings of -$0.40 Per ShareViveve Medical (VIVE) Expected to Announce Earnings of -$0.40 Per Share
www.americanbankingnews.com - May 12 at 3:16 AM
Viveve Medical (VIVE) Downgraded to "Hold" at Craig HallumViveve Medical (VIVE) Downgraded to "Hold" at Craig Hallum
www.americanbankingnews.com - May 11 at 8:03 PM
Viveve Medical (VIVE) Releases Quarterly  Earnings Results, Misses Expectations By $0.05 EPSViveve Medical (VIVE) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 11 at 4:54 PM
U.S. STOCKS ON THE MOVE-Symantec, Trade Desk, Huya, Viveve MedicalU.S. STOCKS ON THE MOVE-Symantec, Trade Desk, Huya, Viveve Medical
www.nasdaq.com - May 11 at 4:52 PM
Viveve Medical (VIVE) Names Scott Durbin as CEOViveve Medical (VIVE) Names Scott Durbin as CEO
www.streetinsider.com - May 11 at 4:52 PM
Viveve Medical (VIVE) PT Lowered to $4 at Mizuho SecuritiesViveve Medical (VIVE) PT Lowered to $4 at Mizuho Securities
www.streetinsider.com - May 11 at 4:52 PM
BRIEF-Viveve Reports Q1 Loss Per Share $0.49BRIEF-Viveve Reports Q1 Loss Per Share $0.49
www.reuters.com - May 11 at 10:13 AM
Viveve Medicals (VIVE) CEO Scott Durbin on Q1 2018 Results - Earnings Call TranscriptViveve Medical's (VIVE) CEO Scott Durbin on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:13 AM
Edited Transcript of VIVE earnings conference call or presentation 10-May-18 9:00pm GMTEdited Transcript of VIVE earnings conference call or presentation 10-May-18 9:00pm GMT
finance.yahoo.com - May 11 at 10:13 AM
Viveve Medical (VIVE) Receives Consensus Recommendation of "Buy" from BrokeragesViveve Medical (VIVE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 10 at 7:22 PM
BRIEF-Viveve Appoints Scott Durbin As Chief Executive OfficerBRIEF-Viveve Appoints Scott Durbin As Chief Executive Officer
www.reuters.com - May 10 at 4:43 PM
Viveve Reports First Quarter 2018 Financial ResultsViveve Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 4:43 PM
Viveve Appoints Scott Durbin as Chief Executive OfficerViveve Appoints Scott Durbin as Chief Executive Officer
finance.yahoo.com - May 10 at 4:43 PM
Viveve to Announce First Quarter 2018 Financial ResultsViveve to Announce First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 9:08 AM
Viveve Medical (VIVE) Upgraded by ValuEngine to SellViveve Medical (VIVE) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - May 2 at 2:03 PM
Viveve Medical (VIVE) Set to Announce Earnings on WednesdayViveve Medical (VIVE) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:32 AM
Viveve Medical (VIVE) Expected to Post Quarterly Sales of $4.68 MillionViveve Medical (VIVE) Expected to Post Quarterly Sales of $4.68 Million
www.americanbankingnews.com - April 26 at 2:20 AM
-$0.40 Earnings Per Share Expected for Viveve Medical (VIVE) This Quarter-$0.40 Earnings Per Share Expected for Viveve Medical (VIVE) This Quarter
www.americanbankingnews.com - April 24 at 5:12 PM
Viveve Medical (VIVE) Now Covered by Analysts at Stifel NicolausViveve Medical (VIVE) Now Covered by Analysts at Stifel Nicolaus
www.americanbankingnews.com - April 17 at 7:39 AM
Viveve Medical (VIVE) Given Average Recommendation of "Buy" by BrokeragesViveve Medical (VIVE) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 15 at 7:17 PM
Viveve Medical (VIVE) Stock Rating Lowered by ValuEngineViveve Medical (VIVE) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 10 at 4:28 PM
$4.70 Million in Sales Expected for Viveve Medical (VIVE) This Quarter$4.70 Million in Sales Expected for Viveve Medical (VIVE) This Quarter
www.americanbankingnews.com - April 9 at 2:18 AM
-$0.42 EPS Expected for Viveve Medical (VIVE) This Quarter-$0.42 EPS Expected for Viveve Medical (VIVE) This Quarter
www.americanbankingnews.com - April 7 at 5:20 PM
Helius Medical Technologies (HSDT) versus Viveve Medical (VIVE) Head to Head ReviewHelius Medical Technologies (HSDT) versus Viveve Medical (VIVE) Head to Head Review
www.americanbankingnews.com - March 31 at 9:12 PM
Q1 2018 Earnings Forecast for Viveve Medical Inc (VIVE) Issued By Zacks Investment ResearchQ1 2018 Earnings Forecast for Viveve Medical Inc (VIVE) Issued By Zacks Investment Research
www.americanbankingnews.com - March 30 at 6:52 AM
VIVE: Q4 Results: 108% Sales Growth in Q4. 2018 Catalysts Include Doubling+ Sales Force, SUI-Related Adoption, VIVEVE IIVIVE: Q4 Results: 108% Sales Growth in Q4. 2018 Catalysts Include Doubling+ Sales Force, SUI-Related Adoption, VIVEVE II
finance.yahoo.com - March 29 at 4:40 PM
$4.67 Million in Sales Expected for Viveve Medical Inc (VIVE) This Quarter$4.67 Million in Sales Expected for Viveve Medical Inc (VIVE) This Quarter
www.americanbankingnews.com - March 23 at 2:48 AM
Viveve Medical (VIVE) Gains FDA Approval for IDE for VIVEVE II Clinical StudyViveve Medical (VIVE) Gains FDA Approval for IDE for VIVEVE II Clinical Study
www.streetinsider.com - March 22 at 9:19 AM
Viveve Medical Inc (VIVE) Given Consensus Rating of "Buy" by AnalystsViveve Medical Inc (VIVE) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 21 at 7:36 PM
Zacks: Brokerages Anticipate Viveve Medical Inc (VIVE) Will Post Earnings of -$0.43 Per ShareZacks: Brokerages Anticipate Viveve Medical Inc (VIVE) Will Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - March 21 at 7:18 PM
Viveve Medical (VIVE) Gains FDA Approval for IDE for VIVEVE II Clinical Study - StreetInsider.comViveve Medical (VIVE) Gains FDA Approval for IDE for VIVEVE II Clinical Study - StreetInsider.com
www.streetinsider.com - March 20 at 4:49 PM
Viveve Medical (VIVE) Earns "Buy" Rating from MizuhoViveve Medical (VIVE) Earns "Buy" Rating from Mizuho
www.americanbankingnews.com - March 20 at 10:48 AM
BRIEF-Viveve Says FDA Signs Off On Clinical StudyBRIEF-Viveve Says FDA Signs Off On Clinical Study
www.reuters.com - March 19 at 10:00 AM
Viveve Announces FDA Approval of IDE to Conduct VIVEVE II Clinical StudyViveve Announces FDA Approval of IDE to Conduct VIVEVE II Clinical Study
finance.yahoo.com - March 19 at 10:00 AM
Colorado womens sexual health company expandingColorado women's sexual health company expanding
www.bizjournals.com - March 16 at 4:52 PM
Edited Transcript of VIVE earnings conference call or presentation 15-Mar-18 9:00pm GMTEdited Transcript of VIVE earnings conference call or presentation 15-Mar-18 9:00pm GMT
finance.yahoo.com - March 16 at 4:52 PM
Viveve Medical (VIVE) Given "Buy" Rating at Maxim GroupViveve Medical (VIVE) Given "Buy" Rating at Maxim Group
www.americanbankingnews.com - March 16 at 3:00 PM
Colorado womens sexual health company expanding; Q4, 2017 revenues riseColorado women's sexual health company expanding; Q4, 2017 revenues rise
www.bizjournals.com - March 16 at 10:04 AM
Viveve Medical (VIVE) Announces  Earnings Results, Misses Estimates By $0.06 EPSViveve Medical (VIVE) Announces Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - March 16 at 8:52 AM
Viveve Medical (VIVE) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowViveve Medical (VIVE) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 4:43 PM
Viveve Reports Fourth Quarter and Full Year 2017 Financial ResultsViveve Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 15 at 4:43 PM
Viveve Medical (VIVE) Set to Announce Quarterly Earnings on ThursdayViveve Medical (VIVE) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 13 at 8:17 PM
Viveve to Announce Financial Results for Fourth Quarter and Year End 2017Viveve to Announce Financial Results for Fourth Quarter and Year End 2017
finance.yahoo.com - March 8 at 10:30 AM
$5.09 Million in Sales Expected for Viveve Medical Inc (VIVE) This Quarter$5.09 Million in Sales Expected for Viveve Medical Inc (VIVE) This Quarter
www.americanbankingnews.com - March 6 at 5:50 AM
 Analysts Expect Viveve Medical Inc (VIVE) to Post -$0.46 EPS Analysts Expect Viveve Medical Inc (VIVE) to Post -$0.46 EPS
www.americanbankingnews.com - March 4 at 3:10 PM

SEC Filings

Viveve Medical (NASDAQ:VIVE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Viveve Medical (NASDAQ:VIVE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Viveve Medical (NASDAQ VIVE) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.